Where is the live CopyMark page for USPTO serial 79016306?

The live record is at https://getcopymark.com/trademark/79016306. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns NEOCHEMICAL?

According to the public USPTO record for serial number 79016306, the listed owner(s) include: NEOCHEMICAL DESARROLLOS AVANZADOS, S.A., NEOCHEMICAL DESARROLLOS AVANZADOS, S.A., NEOCHEMICAL DESARROLLOS AVANZADOS, S.A..

What is USPTO serial number 79016306?

Serial number 79016306 is the USPTO application identifier for the mark NEOCHEMICAL. It is used to track examination, publication, and registration of this trademark.

Which trademark classes cover NEOCHEMICAL?

The public record lists International Classes: 005. Each class corresponds to categories of goods or services identified in the application or registration.

4.9/5

USPTO serial 79016306

NEOCHEMICAL

Q: What is the current status of NEOCHEMICAL?

NEOCHEMICAL (79016306) currently shows USPTO status code 404 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Reviewed by CopyMark Law Group

Reg. 3187604Status 404

Filing date: Jul 19, 2005
Status date: Jul 20, 2015
Registration date: Dec 19, 2006
Examiner: NELSON, EDWARD
Law office: PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NEOCHEMICAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jan Tamulewicz

JAN TAMULEWICZ KATTEN MUCHIN ROSENMAN LLP575 MADISON AVENEW YORK, NY 10022-2585UNITED STATES

Goods and services

Class	Description	Status	First use
005	Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of central nervous system diseases and disorders, namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of neurological diseases and disorders, namely brain injury, spinal cord injury, seizure disorders, Alzheimer's, Huntington's disease, cerebral palsy; pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of gastrointestinal /diseases and disorders; pharmaceutical preparations for the treatment of musculoskeletal diseases and disorders, namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of hypertension; pharmaceutical preparations for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of sexual dysfunction; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of migraines; pharmaceutical preparations for the treatment of pain, namely headaches, migraines, back pain, pain from burns, neuropathic pain; pharmaceutical preparations for the treatment of obesity; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of immunological diseases and disorders, namely autoimmune diseases, immunologic deficiency syndromes, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for the treatment of viral diseases and disorders, namely herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely mood disorders, anxiety disorders, panic disorders, cognitive disorders, schizophrenia, depression; pharmaceutical preparations for the treatment of substance abuse disorders, namely alcoholism and drug addiction; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of yeast infections; pharmaceutical preparations for the treatment of prostate disorders; pharmaceutical preparations for the treatment of pulmonary disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for the treatment of gynecological disorders, namely premenstrual syndrome, endometreosis, yeast infections, menstrual irregularities; pharmaceutical preparations, namely cholesterol preparations, namely preparations to lower cholesterol; pharmaceutical preparations for use in smoking cessation preparations; pharmaceutical preparations for use in tissue and skin repair preparations; pharmaceutical preparations for use in acne medication; pharmaceutical preparations for use in allergy medication; pharmaceutical preparations for use in antacids; pharmaceutical preparations for use in anthelmintics; pharmaceutical preparations for use in antiarrhythmics; pharmaceutical preparations for use in antibiotics; pharmaceutical preparations for use in anticoagulants; pharmaceutical preparations for use in anticonvulsants; pharmaceutical preparations for use in antidepressants; pharmaceutical preparations for use in antiemetics; pharmaceutical preparations for use in antiflatulants; pharmaceutical preparations for use in antihistamines; pharmaceutical preparations for use in antihypertensives; pharmaceutical preparations for use in anti-infectives; pharmaceutical preparations for use in anti-inflammatories; pharmaceutical preparations for use in antiparasitics; pharmaceutical preparations for use in antibacterials; pharmaceutical preparations for use in antifungals; pharmaceutical preparations for use in antivirals; pharmaceutical preparations for use in burn relief medication; pharmaceutical preparations for use in calcium channel blockers; pharmaceutical preparations for use in central nervous system depressants; pharmaceutical preparations for use in central nervous system stimulants; pharmaceutical preparations for use in cough treatment medication; pharmaceutical preparations for use in diarrhea medication; pharmaceutical preparations for use in gastrointestinal medication; pharmaceutical preparations for use in glaucoma agents; pharmaceutical preparations for use in hydrocortisone; pharmaceutical preparations for use in hypnotic agents; pharmaceutical preparations for use in sedatives; pharmaceutical preparations for use in ophthalmic preparations; veterinary preparations, namely, antibiotics, antiparasitics, antiseptics, antimycotics, antihistamines, anti-inflammatories, local anaesthetics, biomaterials, veins therapeutics, antidiabetics, antirheumatics, moisturizers, analgesics, cortico steroids, vitamins, anti-asthmatics, cytostatics, vaccines, veterinary preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, Bluecomb, pneumonia; veterinary preparations for animals and poultry to give newborn animals and birds a healthy start; veterinary preparations for the treatment of vitamin deficiencies; veterinary preparations for the treatment of nutritional muscular dystrophy; veterinary preparations for the treatment of arthritis, muscle soreness and sprains; veterinary preparations for udder care; veterinary preparations for the treatment of parasites; veterinary pharmaceuticals for parturition induction in swine; veterinary preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections, topical infections; veterinary preparations for the treatment of swine bacterial infectious diseases; veterinary preparations for the treatment of infectious diseases in poultry; veterinary preparations for respiratory and reproductive diseases in cattle; veterinary preparations for periodontal diseases; veterinary preparations for the treatment of bacterial infections in dogs; sanitary preparations for medical purposes; dietetic foods adapted for medical use, food for babies; medical plasters, bandages for dressings; material for stopping teeth, dental wax; all purpose disinfectants; preparations for destroying vermin; fungicides, herbicides for agricultural use; sanitary sterilizing compositions; antiseptic preparations; disinfectant compositions for hygienic purposes	SECTION 71 - CANCELLED	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Feb 5, 2016	DENC	NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED	—
Feb 5, 2016	DETH	DEATH OF INTERNATIONAL REGISTRATION	—
Jun 5, 2015	INNT	TOTAL INVALIDATION PROCESSED BY THE IB	—
Jan 8, 2015	NREP	NEW REPRESENTATIVE AT IB RECEIVED	—
Nov 3, 2014	XXSS	GENERIC MADRID TRANSACTION SENT TO IB	—
Nov 3, 2014	XXCR	GENERIC MADRID TRANSACTION CREATED	—
May 27, 2014	INTR	TOTAL INVALIDATION OF REG EXT PROTECTION CREATED	—
Sep 27, 2013	C71T	CANCELLED SECTION 71	—
Dec 21, 2012	NREP	NEW REPRESENTATIVE AT IB RECEIVED	—
Mar 28, 2008	FINO	FINAL DECISION TRANSACTION PROCESSED BY IB	—
Jul 25, 2007	FICS	FINAL DISPOSITION NOTICE SENT TO IB	—
Jul 25, 2007	FIMP	FINAL DISPOSITION PROCESSED	—
Jul 24, 2007	FICR	FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB	—
Dec 19, 2006	R.PR	REGISTERED-PRINCIPAL REGISTER	Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 3, 2006	PUBO	PUBLISHED FOR OPPOSITION	Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 13, 2006	NPUB	NOTICE OF PUBLICATION	—
Aug 5, 2006	PREV	LAW OFFICE PUBLICATION REVIEW COMPLETED	—
Aug 4, 2006	ALIE	ASSIGNED TO LIE	—
Jul 18, 2006	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Jun 24, 2006	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
May 26, 2006	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
May 26, 2006	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 16, 2006	ARAA	ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 16, 2006	REAP	TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED	—
Mar 3, 2006	RFNT	REFUSAL PROCESSED BY IB	—
Feb 13, 2006	RFCS	NON-FINAL ACTION MAILED - REFUSAL SENT TO IB	—
Feb 10, 2006	RFRR	REFUSAL PROCESSED BY MPU	—
Feb 9, 2006	RFCR	NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW	—
Feb 8, 2006	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 7, 2006	DOCK	ASSIGNED TO EXAMINER	—
Nov 10, 2005	NWAP	NEW APPLICATION ENTERED	—
Nov 3, 2005	REPR	SN ASSIGNED FOR SECT 66A APPL FROM IB	—